Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- European Panel Backs Enhertu Label Expansion, Quizartinib: Daiichi Sankyo
September 20, 2023
- Xtandi Accepted for Review for mHSPC in China: Astellas
September 20, 2023
- Iveric Bio’s AMD Med Nets Positive PIII Topline Data in Geographic Atrophy: Astellas
September 20, 2023
- 2 Big Wholesalers Ink Capital Tie-Up with Telehealth Player MICIN
September 19, 2023
- JT Files Tapinarof Cream for Eczema, Psoriasis in Japan
September 19, 2023
- Ex-Takeda Japan Chief Becomes Advisor for Regenerative Medicine Player
September 15, 2023
- Astellas to Set Up New Aseptic Drug Plant in Ireland
September 15, 2023
- AbbVie Files Skyrizi for Ulcerative Colitis in Japan
September 15, 2023
- Oral Flu Drug Prescriptions 10 Times More than Pre-COVID: August Survey
September 15, 2023
- FDA Accepts for Review Takeda’s Entyvio SC Form for Crohn’s
September 15, 2023
- Gilead’s Multi-Drug Resistant HIV Med Now Available in Japan
September 14, 2023
- Xtandi Accepted for EMA Review for Earlier Type of Prostate Cancer
September 14, 2023
- Pfizer Japan Files 20-Valent Pneumococcal Jab for Older Adults, High-Risk People
September 14, 2023
- Daiichi Sankyo Aims to Develop ADC DS-7300 beyond Current 4 Cancers: Exec
September 13, 2023
- GARDP, Indian Firm Ink Deal to Expand Access to Shionogi Antibiotic
September 13, 2023
- Eisai Sets Up Digital Biz Unit to Build Dementia Ecosystem
September 13, 2023
- Takeda Shoots for 80% Cut in Paper Materials, Switch to All-EV/HV Fleet by FY2025
September 12, 2023
- Daiichi Sankyo’s HER3 ADC Posts Positive PII Data in 3rd Line NSCLC, US Filing Eyed by March
September 12, 2023
- EA Pharma, China’s TransThera Hook Up on GI Drug Research
September 12, 2023
- GSK Files Myelofibrosis Drug Momelotinib in Japan
September 12, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…